Superworth

Bausch Health Companies revenue BHC

Sales by quarter and over the last twelve months, from 2009.

Last 12 months, to Sep 30, 2026
$11.1B
Latest quarter, Q3 FY26
$2.9B
+10% on a year earlier
Fiscal year 2025
$10.3B
+7% on the year before

Bausch Health Companies' revenue was $11.1B over the twelve months to Sep 30, 2026, up 11% on a year earlier.

In its latest quarter, Q3 FY26, it was $2.9B, up 10% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 5% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$10.3B+7%
FY2024$9.6B+10%
FY2023$8.8B+8%
FY2022$8.1B−4%
FY2021$8.4B+5%
FY2020$8B−7%
FY2019$8.6B+3%
FY2018$8.4B−4%
FY2017$8.7B−10%
FY2016$9.7B−7%
FY2015$10.4B+27%
FY2014$8.2B+42%
FY2013$5.8B+63%
FY2012$3.5B+44%
FY2011$2.5B+109%

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY26$2.9B+10%$11.1B
Q2 FY26$2.9B+13%$10.9B
Q1 FY26$2.5B+12%$10.5B
Q4 FY25$2.8B+9%$10.3B
Q3 FY25$2.7B+7%$10B
Q2 FY25$2.5B+5%$9.9B
Q1 FY25$2.3B+5%$9.7B
Q4 FY24$2.6B+6%$9.6B
Q3 FY24$2.5B+12%$9.5B
Q2 FY24$2.4B+11%$9.2B
Q1 FY24$2.2B+11%$9B
Q4 FY23$2.4B+10%$8.8B

Against its peers

Companies in Drug Manufacturers - General nearest Bausch Health Companies' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
BHCBausch Health Companies$11.1B+11% a year
NRIXNurix Therapeutics$701.9M
OGNOrganon$6.1B−3% a year
LQDALiquidia$450.9M
PBHPrestige Consumer Healthcare$1.1B−1% a year
ARQTArcutis Biotherapeutics$464M+76% a year
HRMYHarmony Biosciences$959.9M+24% a year
INDVIndivior Pharmaceuticals$1.4B+16% a year
ANIPANI Pharmaceuticals$978.4M+31% a year
PAHCPhibro Animal Health$1.5B+17% a year
LGNDLigand Pharmaceuticals$290.5M+55% a year
Peer median$969.1M

Where Bausch Health Companies ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Bausch Health Companies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.